Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 21;10(6):ofad223. doi: 10.1093/ofid/ofad223

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 1. — Screening, enrollment, and follow-up at 1 month of health care personnel aged 18–65 years in an open-label immunogenicity trial of cell culture–based, recombinant, and standard-and high-dose conventional egg-based influenza vaccines, 2019–2020 influenza season. “n” indicates total number of participants per level (number of newly enrolled season 2 participants at each level). Abbreviations: ccIIV4, cell culture–based inactivated influenza vaccine represented by Flucelvax Quadrivalent by Seqirus; HD-IIV3, high-dose trivalent inactivated influenza vaccine represented by Fluzone High-Dose by Sanofi Pasteur; RIV4, recombinant inactivated influenza vaccine represented by Flublok Quadrivalent by Sanofi Pasteur; SD-IIV4, standard-dose quadrivalent inactivated influenza vaccine represented by Fluzone Quadrivalent by Sanofi Pasteur.